Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-29

Clinical Trial Update: Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Nidufexor in diabetic nephropathy reports safety, tolerability, and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nidufexor (Nidufexor)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetic Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2022-06-29